“太平洋医药”君实生物公司点评:拓益收入同比增长 46%,关注 DKK1 胃肠道肿瘤早期数据

新浪财经
09 May

(转自:市场投研资讯)拓益销售收入保持高增速,公司运营效率显著提升,在手现金 30 亿元。2025 年第一季度公司实现收入 5 亿元(同比+31.46%), 其中,核心产品特瑞普利单抗于国内市场实现销售收入 4.47 亿元(同比+45.72%)。同时,公司积极落实“提质增效重回报”行动方案,提升销售效率,并将资源聚焦于更具潜力的研发项目,与上年同期相比亏损减少。2025Q1 销售费用 2.26 ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10